Analyzing Antares Pharma (ATRS) and Cytori Therapeutics (CYTX)
Antares Pharma (NASDAQ: ATRS) and Cytori Therapeutics (NASDAQ:CYTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.
This table compares Antares Pharma and Cytori Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
34.9% of Antares Pharma shares are held by institutional investors. Comparatively, 10.8% of Cytori Therapeutics shares are held by institutional investors. 11.6% of Antares Pharma shares are held by company insiders. Comparatively, 1.9% of Cytori Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Volatility and Risk
Antares Pharma has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Comparatively, Cytori Therapeutics has a beta of 3.56, meaning that its share price is 256% more volatile than the S&P 500.
Earnings & Valuation
This table compares Antares Pharma and Cytori Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Antares Pharma||$52.22 million||5.85||-$24.33 million||($0.11)||-17.73|
|Cytori Therapeutics||$4.66 million||2.26||-$22.04 million||($0.90)||-0.33|
Cytori Therapeutics has lower revenue, but higher earnings than Antares Pharma. Antares Pharma is trading at a lower price-to-earnings ratio than Cytori Therapeutics, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current ratings for Antares Pharma and Cytori Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Antares Pharma currently has a consensus target price of $3.95, indicating a potential upside of 102.56%. Cytori Therapeutics has a consensus target price of $3.65, indicating a potential upside of 1,116.67%. Given Cytori Therapeutics’ higher possible upside, analysts clearly believe Cytori Therapeutics is more favorable than Antares Pharma.
Antares Pharma beats Cytori Therapeutics on 11 of the 15 factors compared between the two stocks.
About Antares Pharma
Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. The Company’s subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.
About Cytori Therapeutics
Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient’s own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.